azimilide has been researched along with Atrial Fibrillation in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 21 (95.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conway, E; Kowey, PR; Musco, S | 1 |
| Kobayashi, Y | 1 |
| Connolly, SJ; Marcello, SR; Page, RL; Pritchett, EL; Schnell, DJ; Tilsch, TW; Wilkinson, WE | 1 |
| Hara, M; Kanki, H; Kurita, Y; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Shiroshita-Takeshita, A; Takatsuki, S | 1 |
| Connolly, SJ; Marcello, SR; Page, RL; Pritchett, EL; Schnell, DJ; Wilkinson, WE | 3 |
| Marcello, SR; Pritchett, EL | 1 |
| Singh, S | 1 |
| Al-Khalidi, HR; Brum, JM; Camm, AJ; Holroyde, MJ; Karam, R; Pratt, CM; Schwartz, PJ; Sonnenblick, EH; Spyt, MJ | 1 |
| Al-Khalidi, HR; Brum, JM; Camm, AJ; Holroyde, MJ; Marcello, SR; Pratt, CM; Schwartz, PJ; Singh, SN | 1 |
| Pürerfellner, H | 1 |
| Connolly, S; Kerr, C; Kowey, P; Page, RL; Pritchett, EL; Wilkinson, WE | 1 |
| Connolly, SJ; Kerr, CR; Kowey, P; Page, RL; Pritchett, EL; Ruda, MY; Ruzyllo, W; Wilkinson, WE | 1 |
| Borggrefe, M; Lombardi, F; Lüderitz, B; Ruzyllo, W | 1 |
| Connolly, S; Page, RL; Pritchett, EL; Wilkinson, WE | 1 |
| Nakaya, H; Nishida, A; Ogura, T; Reien, Y; Tamagawa, M; Uemura, H; Yabana, H | 1 |
| Camm, J; Savelieva, I | 1 |
| Liu, L; Nattel, S; St-Georges, D | 1 |
| Conway, DS; Lip, GY | 1 |
| Bianconi, L; Castro, A; Santini, M | 1 |
| Connolly, SJ; Marcello, SR; Page, RL; Pritchett, EL; Schnell, D; Schulte, MC; Wilkinson, WE | 1 |
8 review(s) available for azimilide and Atrial Fibrillation
| Article | Year |
|---|---|
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazolidines; Piperazines; Pyrrolidines | 2008 |
[Current strategies of pharmacological and non-pharmacological treatment in atrial fibrillation and atrial flutter].
Topics: Atrial Fibrillation; Atrial Flutter; Body Surface Potential Mapping; Catheter Ablation; Clinical Trials as Topic; Electrophysiology; Humans; Hydantoins; Imidazoles; Imidazolidines; Pacemaker, Artificial; Piperazines; Sulfonamides | 2002 |
Azimilide for atrial fibrillation: clinical trial results and implications.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Hydantoins; Imidazoles; Imidazolidines; Myocardial Infarction; Piperazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Indoles; Oxazines; Phenethylamines; Piperazines; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides | 2004 |
Recent developments in cardiovascular drug therapy: treatment of atrial arrhythmias with new class III drugs and beyond.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Electric Countershock; Electrophysiology; Humans; Hydantoins; Imidazolidines; Pacemaker, Artificial; Phenethylamines; Piperazines; Sulfonamides | 2004 |
Update on atrial fibrillation: part II.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Humans; Hydantoins; Imidazolidines; Piperazines; Pulmonary Veins | 2008 |
New antiarrhythmic agents for atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hydantoins; Imidazoles; Imidazolidines; Lidocaine; Phenethylamines; Piperazines; Sulfonamides | 2001 |
New antiarrhythmic drugs for the treatment of atrial fibrillation.
Topics: Aminobenzoates; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2002 |
10 trial(s) available for azimilide and Atrial Fibrillation
| Article | Year |
|---|---|
Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Humans; Hydantoins; Imidazoles; Imidazolidines; Kinetics; Male; Middle Aged; Piperazines; Secondary Prevention | 2003 |
Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Chest Pain; Dizziness; Double-Blind Method; Dyspnea; Fatigue; Heart Rate; Humans; Hydantoins; Imidazoles; Imidazolidines; Piperazines; Recurrence | 2003 |
Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Double-Blind Method; Female; Heart Rate; Humans; Hydantoins; Imidazoles; Imidazolidines; Life Tables; Male; Middle Aged; Myocardial Infarction; Neutropenia; Piperazines; Potassium Channel Blockers; Risk Factors; Survival Analysis; Torsades de Pointes; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Hydantoins; Hypertension; Imidazoles; Imidazolidines; Male; Middle Aged; Neutropenia; Piperazines; Prevalence; Systole; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Female; Heart Rate; Humans; Hydantoins; Imidazolidines; Long QT Syndrome; Male; Middle Aged; Piperazines; Syncope; Torsades de Pointes; Treatment Outcome | 2006 |
Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Confidence Intervals; Coronary Disease; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hydantoins; Imidazolidines; Male; Middle Aged; Piperazines; Tachycardia, Paroxysmal; Treatment Outcome | 2006 |
Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Humans; Hydantoins; Imidazolidines; Male; Middle Aged; Piperazines; Sotalol; Treatment Outcome | 2006 |
Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Endpoint Determination; Female; Humans; Hydantoins; Imidazolidines; Male; Piperazines; Secondary Prevention; Tachycardia, Supraventricular; Treatment Outcome | 2008 |
Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Humans; Hydantoins; Imidazoles; Imidazolidines; Male; Middle Aged; Piperazines; Treatment Outcome | 2000 |
Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
Topics: Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hydantoins; Imidazoles; Imidazolidines; Male; Piperazines | 2002 |
4 other study(ies) available for azimilide and Atrial Fibrillation
| Article | Year |
|---|---|
Preserved effects of potassium channel blockers in the pacing-induced remodeled canine atrium: a comparison between E4031 and azimilide.
Topics: Animals; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Dogs; Electric Stimulation; Electrocardiography; Electrodes, Implanted; Female; Hydantoins; Imidazoles; Imidazolidines; Male; Piperazines; Piperidines; Potassium Channel Blockers; Pyridines; Refractory Period, Electrophysiological | 2003 |
Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts.
Topics: Action Potentials; Animals; Atrial Fibrillation; Carbachol; Delayed Rectifier Potassium Channels; Dose-Response Relationship, Drug; Female; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Heart Atria; Hydantoins; Imidazolidines; In Vitro Techniques; Muscarinic Antagonists; Patch-Clamp Techniques; Piperazines; Potassium Channel Blockers; Refractory Period, Electrophysiological | 2007 |
Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Dogs; Drug Administration Schedule; Electrocardiography; Female; Heart Atria; Heart Rate; Hydantoins; Imidazoles; Imidazolidines; Male; Phenethylamines; Piperazines; Potassium Channel Blockers; Sulfonamides | 1998 |
Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydantoins; Imidazoles; Imidazolidines; Male; Middle Aged; Myocardial Ischemia; Piperazines; Randomized Controlled Trials as Topic; Recurrence | 2001 |